NASDAQ
467.54USD
+20.45 (+4.57%)
We have scored 16 news catalysts on Madrigal Pharmaceuticals, Inc. (MDGL) over the past 12 months. The biggest single-day move next to one of them came Jun 3, 2026, when MDGL closed +7.8%: “Madrigal Pharmaceuticals Could Become The Next Vertex”. Coverage across the window leans positive (average ticker sentiment +0.51). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.8B
P/E
—
EPS
—
Beta
-1.05
52W range
393.61-615
Day range
451.23–470.30
Open
451.23
Prev close
447.09
Volume
408K
Avg volume
325.1K
Dividend
0.00
IPO
2007-02-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Madrigal Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Madrigal Pharmaceuticals, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MDGL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
